On October 1–2, 2025, the Securing Access through End-to-End Design Workshop took place at the Global Health Campus in Geneva. The event was organized by Unitaid, Clinton Health Access Initiative (CHAI), the Center for Global Health Policy & Politics at Georgetown University, and Treatment Action Group (TAG).

This meeting built on the previous year’s workshop, where partners came together to define key principles for ensuring access to health technologies. In 2024, the discussions were more conceptual: participants worked to align on approaches and began developing Target Access Profiles (TAPs) — strategic frameworks for access to medical products.

This year, the focus shifted toward practice: participants began developing concrete Access Roadmaps for three product categories:

  • Long-acting formulations (including for HIV and TB),

  • Near point-of-care diagnostics,

  • Medical oxygen.

Key goals of the workshop included:

  • Testing and refining the methodology for access planning.

  • Defining the roles of different stakeholders (governments, donors, manufacturers, communities) across the product lifecycle — from development to scale-up.

  • Aligning on approaches that allow access conditions (e.g. pricing, licensing, technology transfer, regulatory pathways) to be embedded as early as the clinical trial design stage.

Denis Godlevskiy, Regional Coordinator of ITPC EECA, participated in the working group on long-acting formulations and emphasized: “The goal of the workshop was to understand what principles must be embedded already at the design and development stages of clinical research — so that we don’t end up facing artificial access barriers later. Without systemic investment in health infrastructure, no rollout will be sustainable. We also need long-term support for communities, especially for community-led monitoring (CLM) initiatives, because many NGOs and community groups in the region are now fighting for survival instead of leading meaningful advocacy and service delivery. If partners focus only on products and ignore people, these technologies will simply gather dust in empty clinics.”